Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts
Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and Yescarta™) were recently approved by the FDA. Kymriah™ is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and Yescarta™ is for the tre...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | anglais |
| Publié: |
2018
|
| Accès en ligne: | https://doi.org/10.1016/j.drudis.2018.02.012 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|